User:Ceyockey/WPReqArticle BeiGene-Entry

BeiGene, Ltd. (alternatively Beigene Co. Ltd.) was founded in Beijing, China in 2010. The company's focus from inception to the present has been in the oncology therapeutic area, including the development of a proprietary cancer biology platform, based on a library of human cancer samples. The company is engaged in small molecule, immunologic, and combined small-large molecule therapeutic development.

History
BeiGene was founded in Beijing, China in 2010 as a pre-clinical research and development company, on the premise of becoming "the Genentech of China". One of the founders, John Oyler, put up US$10 million of his own money as seed funding for the venture.

By 2013 it had begun running clinical trials. As of the 2017 partnership with Celgene, the company became a commercial pharmaceutical company.

Celgene
The company's partnership with Celgene in 2018 related to clinical development of tislelizumab, a PD-1 inhibitor, as a second line treatment for Hodgkin's lymphoma, with plans to expand to several solid tumor cancers. This partnership involved a US$1.4 billion infusion of capital by Celgene into BeiGene, in addition to development milestone payments. Celgene expects to be able to market the drug worldwide outside of China.

Celgene has also granted BeiGene exclusive rights to sell the cancer drugs revlimid, abraxane and vidaza in China until around 2027.

Merck
BeiGene's partnership with Merck Serono focused on development of pamiparib, a PARP inhibitor, also known as Beigene-290, positioned as a cancer cell killing assist. In exchange, Merck provided development milestone payments and expects to be able to sell the drug worldwide except in China and Germany. BeiGene has also licenced a pre-clinical BRAF inhibitor to Merck.

Key personnel
According to a report in 2018, the company's executive team was made up of Chinese and "international executives".

, the company's chief executive officer, also a co-founder, was John V. Oyler. an American. Co-founding with Oyler in 2010 was Wang Xiaodong, a member of the US National Academy of Sciences.

, the company's chief financial officer was Howard Liang.

, the company's chief medical officer (in hematology) was Jane Huang.

As of 2018, the head of the company's Chinese operations was Wu Xiaobin.

Fundraising
Nasdaq began listing the company in 2016 following an initial public offering of 6.6 million shares at a per share price of US$24, making BeiGene the first company founded in China to secure a listing on the Nasdaq exchange. The Nasdag offering was in American Depository shares, each representing thirteen ordinary shares. BeiGene launched a second intial public offering of 65.6 million shares at a per price share of HK$108 on the HKEX Hong Kong exchange in 2018, which netted the company US$0.9 billion, making it the largest offering for a biotech company on the exchange up to that point. This Hong Kong listing was the first conducted under new rules established by the Hong Kong exchange to encourage an influx of secondary listings, as well as having taken advantage of new HKEX rules meant to encourage an influx of pre-revenue drug developers (pharmas that have yet to generate revenue from drugs on the market).

The firm was running losses as of the second IPO in 2018, specifically US$105 million for the first quarter.